Evidence map›Paper›PMID 34834178›Full record

ArticlePharmaceutics2021

Artepillin C Reduces Allergic Airway Inflammation by Induction of Monocytic Myeloid-Derived Suppressor Cells.

Núbia Sabrina Martins, Thais Fernanda de Campos Fraga-Silva, Giseli Furlan Correa, Mèdéton Mahoussi Michaël Boko, Leandra Naira Zambelli Ramalho, Débora Munhoz Rodrigues, Juliana Issa Hori, Diego Luis Costa, Jairo Kenupp Bastos, Vânia Luiza Deperon Bonato

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Different bacterial cargo in apoptotic cells drive distinct macrophage phenotypes.Apoptosis : an international journal on programmed cell death · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Núbia Sabrina MartinsBasic and Applied Immunology Program, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14049-900, Sao Paulo, Brazil.ORCID 0000-0002-7849-6486
Thais Fernanda de Campos Fraga-SilvaDepartment of Biochemistry and Immunology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14049-900, Sao Paulo, Brazil.ORCID 0000-0002-2053-8938
Giseli Furlan CorreaDepartment of Biochemistry and Immunology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14049-900, Sao Paulo, Brazil.ORCID 0000-0002-6329-0506
Mèdéton Mahoussi Michaël BokoBasic and Applied Immunology Program, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14049-900, Sao Paulo, Brazil.
Leandra Naira Zambelli RamalhoDepartment of Pathology and Legal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14049-900, Sao Paulo, Brazil.
Débora Munhoz RodriguesDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences, University of Sao Paulo, Ribeirao Preto 14049-900, Sao Paulo, Brazil.
Juliana Issa HoriApis Flora Industrial and Comercial Ltda, Ribeirao Preto 14020-670, Sao Paulo, Brazil.ORCID 0000-0002-5421-3728
Diego Luis CostaBasic and Applied Immunology Program, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14049-900, Sao Paulo, Brazil.ORCID 0000-0002-9440-2814
Jairo Kenupp BastosDepartment of Pharmaceutical Sciences, School of Pharmaceutical Sciences, University of Sao Paulo, Ribeirao Preto 14049-900, Sao Paulo, Brazil.
Vânia Luiza Deperon BonatoBasic and Applied Immunology Program, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14049-900, Sao Paulo, Brazil.ORCID 0000-0003-4189-2685
Universidade de São Paulo · BRApis Flora (Brazil) · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/21629-5; 2017/04138-8
6 · The paper itself

Abstract

Propolis is a natural product produced by bees that is primarily used in complementary and alternative medicine and has anti-inflammatory, antibacterial, antiviral, and antitumoral biological properties. Some studies have reported the beneficial effects of propolis in models of allergic asthma. In a previous study, our group showed that green propolis treatment reduced airway inflammation and mucus secretion in an ovalbumin (OVA)-induced asthma model and resulted in increased regulatory T cells (Treg) and polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) frequencies in the lungs, two leukocyte populations that have immunosuppressive functions. In this study, we evaluated the anti-inflammatory effects of artepillin C (ArtC), the major compound of green propolis, in the context of allergic airway inflammation. Our results show that ArtC induces in vitro differentiation of Treg cells and monocytic MDSC (M-MDSC). Furthermore, in an OVA-induced asthma model, ArtC treatment reduced pulmonary inflammation, eosinophil influx to the airways, mucus and IL-5 secretion along with increased frequency of M-MDSC, but not Treg cells, in the lungs. Using an adoptive transfer model, we confirmed that the effect of ArtC in the reduction in airway inflammation was dependent on M-MDSC. Altogether, our data show that ArtC exhibits an anti-inflammatory effect and might be an adjuvant therapy for allergic asthma.

Indexed as

allergic asthmaartepillin CM-MDSCpropolistherapies

Identifiers

PMID34834178
PMCPMC8625726
OpenAlexW3210701958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.